Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.46 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.46 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.38 |
| ▸ | MAOA | P21397 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 4/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.35 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28596603 | 0.81 | ALDH1A1 (0.47) | SIRT1ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL29629334 | 0.81 | ALDH1A1 (0.47) | SIRT1ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL2848169 | 0.81 | TP53 (0.42) | SIRT1KLK5MAOAMAOBALDH1A1 | |
| SCHEMBL28596601 | 0.81 | ALDH1A1 (0.47) | SIRT1ALDH1A1MEN1MAPTKMT2A | |
| SCHEMBL31547349 | 0.78 | MAPT (0.46) | ADORA3SIRT1CYP3A4KLK5ALDH1A1 | |
| SCHEMBL4806205 | 0.78 | MAPT (0.46) | ADORA3SIRT1CYP3A4KLK5ALDH1A1 | |
| SCHEMBL1711344 | 0.77 | CYP2C9 (0.38) | AKR1C3SIRT1KLK5ALDH1A1MAPT | |
| SCHEMBL27893072 | 0.77 | SIRT1 (0.48) | ARADORA3SIRT1KLK5MAOA | |
| SCHEMBL72984 | 0.77 | SIRT1 (0.48) | ARADORA3SIRT1KLK5MAOA | |
| Charcoal, Activated SCHEMBL2025121 | 0.76 | SIRT1 (0.47) | ARADORA3SIRT1KLK5MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4061765-A | LIVER DISORDERS | DR. MADAUS & CO. (DT) | 1977-12-06 | — | — | US | claimed |
| US-3994925-A | USEFUL TO ANTAGONIZE OR MITIGATE LIVER DAMAGE AND INFLAMMATION | DR. MADAUS & CO. (DT) | 1976-11-30 | — | — | US | claimed |
| CN-106511421-B | A method of purification milk thistle Flavone class compound | 江苏中兴药业有限公司 | 2019-05-17 | — | — | CN | disclosed |
| CN-106511421-A | Method for refining flavonoid compounds in stems and leaves of silybum marianum | 江苏中兴药业有限公司 | 2017-03-22 | — | — | CN | disclosed |
| EP-2430017-B1 | A method for preparing AMORPHOUS SILIBININ | MADAUS GMBH (DE) | 2016-06-29 | — | — | EP | disclosed |
| US-8614341-B2 | Amorphous silibinin for the treatment of viral hepatitis | EUROMED S.A. (ES) | 2013-12-24 | — | — | US | disclosed |
| EP-2307405-B1 | COMPOSITION OF FLAVANOLIGNAN AND AMINO ACID WITH IMPROVED WATER SOLUBILITY | AGRA GROUP AS (CZ) | 2013-10-02 | — | — | EP | disclosed |
| US-8426459-B2 | Composition of flavanolignan and amino acid with improved water solubility | AGRA GROUP, A.S. (CZ) | 2013-04-23 | — | — | US | disclosed |
| US-20120108825-A1 | AMORPHOUS SILIBININ FOR THE TREATMENT OF VIRAL HEPATITIS | EUROMED S.A. (ES) | 2012-05-03 | — | — | US | disclosed |
| EP-2430017-A1 | AMORPHOUS SILIBININ FOR THE TREATMENT OF VIRAL HEPATITIS | Euromed SA (ES) | 2012-03-21 | — | — | EP | disclosed |
| US-20110207805-A1 | COMPOSITION OF FLAVANOLIGNAN AND AMINO ACID WITH IMPROVED WATER SOLUBILITY | AGRA GROUP, A.S. (CZ) | 2011-08-25 | — | — | US | disclosed |
| US-6020384-A | SOLID ORAL UNIT DOSAGE FORM; THERAPY OF LIVER DISORDERS | MADAUS AG (DE) | 2000-02-01 | — | — | US | disclosed |
| US-5906991-A | RELEASING AND ABSORPTION, SUSPENSION AND HEATING | DR. MADAUS GMBH & CO (DE) | 1999-05-25 | — | — | US | disclosed |
| US-5714473-A | CHEMOTHERAPY; MIXTURE WITH ALKALI METAL CITRATE | MADAUS AG (DE) | 1998-02-03 | — | — | US | disclosed |
| US-4871763-A | Method of treating liver diseases using pure silibinin | DR. MADAUS GMBH & CO. (DE) | 1989-10-03 | — | — | US | disclosed |
| US-4368195-A | Method for the extraction of silymarin from plants | DR. MADAUS & CO. (DE) | 1983-01-11 | — | — | US | disclosed |
| US-4168318-A | LIVER DISORDERS, OXIDATION OF ALCOHOL TO KETONE | DR. MADAUS & CO. (DE) | 1979-09-18 | — | — | US | disclosed |
| US-4081529-A | EXTRACTS FROM SILYBUM MARIANUM SEEDS, ANTIHEPATOXIC | INVERNI DELLA BEFFA S.P.A. (IT) | 1978-03-28 | — | — | US | disclosed |
| US-4061765-A | LIVER DISORDERS | DR. MADAUS & CO. (DT) | 1977-12-06 | — | — | US | disclosed |
| US-3994925-A | USEFUL TO ANTAGONIZE OR MITIGATE LIVER DAMAGE AND INFLAMMATION | DR. MADAUS & CO. (DT) | 1976-11-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120108825-A1 | AMORPHOUS SILIBININ FOR THE TREATMENT OF VIRAL HEPATITIS | CSTB, PYGL, CCNB1 | AR 4506/4885ADORA3 3980/4885HSD11B1 2173/4885 |
| US-20110207805-A1 | COMPOSITION OF FLAVANOLIGNAN AND AMINO ACID WITH IMPROVED WATER SOLUBILITY | BCAT2, BCAT1, TEAD3 | AR 3054/4885ADORA3 3563/4885HSD11B1 4564/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.